Combinations strategies involving checkpoint immunotherapies were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers. Important advances were also made with respect to immune-related biomarkers, cellular immunotherapies, and personalized vaccines. Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, is focusing her research(...)